1. Brensocatib, a dipeptidyl peptidase 1 inhibitor, reduced pulmonary exacerbations by 21% and slowed lung function decline over 52 weeks in patients with bronchiectasis.
2. The study was a phase III, double-blind, randomized controlled trial with 1,721 patients.
3. Annualized rate of adjudicated pulmonary exacerbations was the primary end point.
4. Both doses of brensocatib showed significant reduction in pulmonary exacerbations compared to placebo.
5. Only the 25-mg dose was associated with a significant reduction in lung function decline.

Source: The New England Journal of Medicine